Open AccessRibociclib in 1st line HR+ breast cancer treatment
Author(s) -
Lyudmila Zhukova,
I. P. Ganshina,
О. О. Гордеева,
E. V. Lubennikova
Publication year - 2018
Publication title -
journal of modern oncology
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/1815-1434_2018.2.38-41
Subject(s) - medicine , breast cancer , clinical trial , cancer , clinical practice , oncology , intensive care medicine , family medicine
Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom